Literature DB >> 6679957

Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.

C Y Pak, K Sakhaee, C J Fuller.   

Abstract

Long-term effects of potassium citrate therapy (usually 60 mEq/day) were examined in 53 patients with renal stones (11 with uric acid lithiasis with complication of calcium stones, 10 with hypocitraturia as the sole abnormality, and 28 with hypocitraturia occurring with other abnormalities such as absorptive hypercalciuria, renal tubular acidosis, hyperuricosuric calcium oxalate nephrolithiasis, and enteric hyperoxaluria). Potassium citrate was given alone in 29 patients, added to thiazide and/or allopurinol treatments in 12 patients who continued to form stones on these treatments, and begun concurrently with thiazide and/or allopurinol in 12 patients with hypocitraturia and other defects (hypercalcuria and/or hyperuricosuria). In all three groups of patients, urinary citrate and pH significantly increased during potassium citrate treatment. Urinary saturation of calcium oxalate significantly declined while that of brushite remained unchanged. The propensity for the spontaneous nucleation of calcium oxalate, determined from the minimum amount of added oxalate required to elicit precipitation, declined. The treatment was effective in preventing new stone formation in all three groups. Stone passage rate declined from 5.14-7.41 stones/patient year before potassium citrate treatment to 0.66-1.33 stones/patient year during treatment, and 75.0-91.7% of patients were in remission. In patients who relapsed on other treatments (with passage of 5.14 stones/patient year), the addition of potassium citrate to the ongoing treatment program reduced stone formation to 1.33 stones/patient year and caused remission in 91.7% of patients. In 14 of 33 patients with preexisting radiopaque stones, there was radiological evidence of a reduced number of stones after 8 months-2 years of potassium citrate treatment. In conclusion, potassium citrate restores normal urinary citrate, decreases saturation and propensity for spontaneous nucleation of calcium oxalate, and inhibits new stone formation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6679957

Source DB:  PubMed          Journal:  Trans Assoc Am Physicians        ISSN: 0066-9458


  9 in total

Review 1.  Do "inhibitors of crystallisation" play any role in the prevention of kidney stones? A critique.

Authors:  William G Robertson
Journal:  Urolithiasis       Date:  2016-11-29       Impact factor: 3.436

2.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 3.  Preventive treatment of nephrolithiasis with alkali citrate--a critical review.

Authors:  D Mattle; B Hess
Journal:  Urol Res       Date:  2005-05-04

4.  Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet.

Authors:  Melanie A McNally; Paula L Pyzik; James E Rubenstein; Rana F Hamdy; Eric H Kossoff
Journal:  Pediatrics       Date:  2009-07-13       Impact factor: 7.124

Review 5.  Kidney stones.

Authors:  Saeed R Khan; Margaret S Pearle; William G Robertson; Giovanni Gambaro; Benjamin K Canales; Steeve Doizi; Olivier Traxer; Hans-Göran Tiselius
Journal:  Nat Rev Dis Primers       Date:  2016-02-25       Impact factor: 52.329

Review 6.  Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease.

Authors:  W G Robertson
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

7.  Impact of age and renal function on urine chemistry in patients with calcium oxalate kidney stones.

Authors:  Triet Vincent M Tran; Xilong Li; Beverley Adams-Huet; Naim M Maalouf
Journal:  Urolithiasis       Date:  2021-02-13       Impact factor: 3.436

8.  Long-Term Therapy With Wu-Ling-San, a Popular Antilithic Chinese Herbal Formula, Did Not Prevent Subsequent Stone Surgery: A Nationwide Population-Based Cohort Study.

Authors:  San-Yuan Wu; Huey-Yi Chen; Kao-Sung Tsai; Jen-Huai Chiang; Chih-Hsin Muo; Fung-Chang Sung; Yung-Hsiang Chen; Wen-Chi Chen
Journal:  Inquiry       Date:  2016-12-07       Impact factor: 1.730

Review 9.  Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.

Authors:  Giovanni Gambaro; Emanuele Croppi; Fredric Coe; James Lingeman; Orson Moe; Elen Worcester; Noor Buchholz; David Bushinsky; Gary C Curhan; Pietro Manuel Ferraro; Daniel Fuster; David S Goldfarb; Ita Pfeferman Heilberg; Bernard Hess; John Lieske; Martino Marangella; Dawn Milliner; Glen M Preminger; Jose' Manuel Reis Santos; Khashayar Sakhaee; Kemal Sarica; Roswitha Siener; Pasquale Strazzullo; James C Williams
Journal:  J Nephrol       Date:  2016-07-25       Impact factor: 3.902

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.